BJMO - volume 19, issue 3, may 2025
S. Loizidis MD, M. Ignatiadis MD, PhD
In recent years, the introduction of circulating tumour DNA (ctDNA) has advanced precision medicine in breast cancer management. Progress in tumour biology and improvements in ctDNA detection assays have enabled its implementation in metastatic breast cancer, with regulatory authorities approving assays for detecting specific mutations to guide treatment selection. In early breast cancer, studies have demonstrated that ctDNA detection during follow-up after definitive treatment is associated with worse outcomes. Ongoing interventional studies are evaluating the clinical utility of ctDNA in this context. Additionally, the potential role of ctDNA in breast cancer screening is under investigation. This review discusses the current indications for ctDNA and ongoing studies in breast cancer.
(BELG J MED ONCOL 2025;19(3): 96–103)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
